Month: August 2024

SFL Corporation Ltd. (“SFL” or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the second quarter of 2024 on Wednesday, August 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Wednesday, August 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following:  A: Join Conference Call Webcast In Listen Only Mode:Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to “Webcast”, or access directly via the webcast link below. The webcast with slideshow will be played live from...

Second Quarter Net Revenue of $147.4 million, up 38.5% versus Prior Year PeriodRaises Fiscal Year 2024 Outlook and Reiterates Long-term GuidancePlans for New State-of-the-Art Egg Washing and Packing Facility in Seymour, Indiana to Drive Growth AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its second quarter ended June 30, 2024. Financial highlights for the second quarter ended June 30, 2024, compared to the second quarter ended June 25, 2023, include:Net Revenue increased 38.5% to $147.4 million, compared to $106.4 million Gross Margin expanded 362 basis points to 39.1%, compared to 35.5% Net Income of $16.3 million, compared to $6.7 million Net Income per Diluted Share of $0.36,...

– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – – Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 – – Updated data on WTX-124 in combination with pembrolizumab and opening of expansion arms anticipated in the second half of 2024 – – Update on WTX-330 dose escalation and expansion data anticipated at a medical meeting in the fourth quarter of 2024 – WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated...

Q2 revenue increased 19% year-over-year to a record $133 million driven by marketplace growth of 25% year-over-year. Q2 gross profit increased 21% year-over-year to a record $52.9 million with a record 39.9% gross margin. Q2 marketplace gross profit increased 33% year-over-year. Q2 marketplace gross margin increased 180 basis points year-over-year to a record 33.5%. Q2 supplier services gross margin increased 910 basis point to 88.9% driven by increased focus on the high gross margin Thomas marketing and advertising services business. Q2 Adjusted EBITDA improved 70% year-over-year to a loss of $2.6 million. Q2 Adjusted EBITDA loss represented 2.0% of revenue.    2024 growth initiatives include: expanding buyer and supplier networks; driving deeper enterprise engagement; further expanding the marketplace menu; growing internationally and...

Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024 Dosing of first patient in a Phase 1 trial for FHD-909, a potential first-in-class SMARCA2 selective inhibitor, anticipated in the second half of 2024; primary target population in SMARCA4 mutated NSCLC IND-enabling studies for Selective CBP degrader program on track to begin by year-end 2024   Successful $110 million financing strengthens balance sheet with cash, cash equivalents and short-term investments of $285.2 million as of June 30, 2024 and extends expected cash runway into 2027 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat...

IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical data expected in Q1 2025 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrated a favorable safety and pharmacodynamic profile at 0.5 mg with a 21 days on/7 days off schedule; dosing ongoing at 0.75 mg using a 21/7 schedule; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024 Achieved first program and financial milestones from strategic research collaboration with Roche Strong cash position expected to fund operations into H1 2027 and through multiple anticipated clinical readouts including from proof-of-concept patient studies for MRT-2359, MRT-6160, and MRT-8102 BOSTON,...

Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-stage Choroidal Melanoma to be Presented at Retina Society Annual Meeting Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We are excited by the progress we made in the second quarter across...

– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data from the RESET-Myositis™ and RESET-SLE™ trials as well as initial clinical data from the RESET-SSc™ and RESET-MG™ trials anticipated in 2H24 – – Initial clinical and translational data from each of the first patients in the RESET-Myositis and RESET-SLE trials presented at EULAR in June 2024 – – An LN patient with very active, refractory disease dosed with CABA-201 in late June experienced a protocol-defined dose-limiting toxicity of Grade 4 ICANS, which resolved rapidly following standard management; the independent data monitoring committee recommended the study to proceed as designed, without delay, at...